[Comment] An HPV vaccine from India: broadening possibilities for cervical cancer control

In The Lancet Oncology, Hitt Sharma and colleagues1 report findings from a pivotal phase 2/3 human papillomavirus (HPV) prophylactic vaccine trial. Briefly, they show that two doses of a quadrivalent virus-like particle (VLP) vaccine targeting HPV types 6, 11, 16, and 18 (Cervavax; Serum Institute of India, Pune, India) induced non-inferior antibody responses in girls and boys aged 9–14 years compared with a quadrivalent HPV vaccine licensed worldwide and targeting the same HPV types (Gardasil; Merck Sharp & Dohme, Harleem, the Netherlands), given in three doses to women aged 15–26 years, an age group in which strong clinical efficacy has been shown.